Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | FLT4 | P35916 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24167390 | 0.82 | EGFR (0.48) | EGFRKDRFLT1FLT4 | |
| SCHEMBL24167380 | 0.79 | ALDH1A1 (0.39) | PDE7AALDH1A1 | |
| SCHEMBL29888087 | 0.73 | EGFR (0.49) | EGFRALDH1A1 | |
| SCHEMBL24569649 | 0.73 | EGFR (0.49) | EGFRALDH1A1 | |
| SCHEMBL18916736 | 0.73 | DYRK1A (0.42) | EGFRKDRFLT1FLT4EGLN2 | |
| SCHEMBL25694520 | 0.72 | PIK3CD (0.36) | EGFRKDRFLT1FLT4MAP4K4 | |
| Hydrochloric Acid SCHEMBL22123553 | 0.71 | DYRK1A (0.41) | EGFRKDRFLT1FLT4EGLN2 | |
| Hydrochloric Acid SCHEMBL29974128 | 0.71 | DYRK1A (0.41) | EGFRKDRFLT1FLT4EGLN2 | |
| SCHEMBL29414877 | 0.71 | ERBB2 (0.48) | EGFR | |
| SCHEMBL24167631 | 0.71 | ENPP1 (0.34) | EGFRKDRFLT1FLT4EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267137-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022006386-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265098-A1 | ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, ERBB3, CHEK2 | EGFR 6/4885KDR 227/4885FLT1 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.